Prevalence of Metabolic Syndrome in Psychiatric Patients
Location
Medical Education Building, LSUHSC-NO
Presentation Date
10-10-2019 10:00 AM
End Date
10-10-2019 12:00 PM
Description
There has been suggested that a correlation exists between patients diagnosed with psychiatric disorders and gut microbiome dysbiosis. Risk factors for the development of metabolic syndrome include diagnosis of psychiatric illness, use of atypical antipsychotic medications, and history of gastrointestinal disease. The purpose of this study was to retrospectively determine the prevalence of metabolic syndrome and its possible correlation with the use of atypical antipsychotics among patients diagnosed with schizophrenia, schizoaffective disorder, bipolar disorder or major depressive disorder. This investigation was accomplished through medical chart reviews of patients of Our Lady of the Lake Regional Medical Center between March 4, 2016 and December 10, 2018.
The patients identified with psychiatric disorders were control-matched with two other patient groups: patients diagnosed with mood/anxiety disorders and patients not diagnosed with any psychiatric disorder. These control patients were also matched to the psychiatric patients in terms of BMI, age, sex, insurance type, race, and ethnicity. Some exclusion criteria for both the psychiatric patient group and control patient groups include past medical history of cigarette smoking, HIV, substance abuse, intellectual disability, traumatic brain injury, or co-morbid conditions such as hypertension, ischemic heart diseases, diabetes, and obesity.
After data collection was complete, the patients from the three groups were classified as either having or not having metabolic syndrome. This classification was assigned based on the presence of three or more of the qualifying criteria for metabolic syndrome or diagnosis of metabolic syndrome in the patient’s medical record. Further, the patients were separated into categories such as the presence/absence of gastrointestinal disease and those who were taking or not taking antipsychotic medications. Prevalence of metabolic syndrome was then calculated among these patient groups.
As this is an ongoing study, a definitive correlation between metabolic syndrome and the use of atypical antipsychotics cannot yet be established for these patients with schizophrenia and/or schizoaffective disorder. However, the data collected so far supports that the majority (55%) of the patients meet the criteria for metabolic syndrome. Though, less than 1% of the patients who meet criteria for MetS have an actual diagnosis of MetS in their medical records.
Recommended Citation
Comardelle, Caroline E., "Prevalence of Metabolic Syndrome in Psychiatric Patients" (2019). Medical Student Research Poster Symposium. 7.
https://digitalscholar.lsuhsc.edu/sommrd/2019/posters/7
Prevalence of Metabolic Syndrome in Psychiatric Patients
Medical Education Building, LSUHSC-NO
There has been suggested that a correlation exists between patients diagnosed with psychiatric disorders and gut microbiome dysbiosis. Risk factors for the development of metabolic syndrome include diagnosis of psychiatric illness, use of atypical antipsychotic medications, and history of gastrointestinal disease. The purpose of this study was to retrospectively determine the prevalence of metabolic syndrome and its possible correlation with the use of atypical antipsychotics among patients diagnosed with schizophrenia, schizoaffective disorder, bipolar disorder or major depressive disorder. This investigation was accomplished through medical chart reviews of patients of Our Lady of the Lake Regional Medical Center between March 4, 2016 and December 10, 2018.
The patients identified with psychiatric disorders were control-matched with two other patient groups: patients diagnosed with mood/anxiety disorders and patients not diagnosed with any psychiatric disorder. These control patients were also matched to the psychiatric patients in terms of BMI, age, sex, insurance type, race, and ethnicity. Some exclusion criteria for both the psychiatric patient group and control patient groups include past medical history of cigarette smoking, HIV, substance abuse, intellectual disability, traumatic brain injury, or co-morbid conditions such as hypertension, ischemic heart diseases, diabetes, and obesity.
After data collection was complete, the patients from the three groups were classified as either having or not having metabolic syndrome. This classification was assigned based on the presence of three or more of the qualifying criteria for metabolic syndrome or diagnosis of metabolic syndrome in the patient’s medical record. Further, the patients were separated into categories such as the presence/absence of gastrointestinal disease and those who were taking or not taking antipsychotic medications. Prevalence of metabolic syndrome was then calculated among these patient groups.
As this is an ongoing study, a definitive correlation between metabolic syndrome and the use of atypical antipsychotics cannot yet be established for these patients with schizophrenia and/or schizoaffective disorder. However, the data collected so far supports that the majority (55%) of the patients meet the criteria for metabolic syndrome. Though, less than 1% of the patients who meet criteria for MetS have an actual diagnosis of MetS in their medical records.
Comments
Mentor: Rebecca Horn, PhD (LSUHSC- Our Lady of the Lake Psychiatry Residency Program)